Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

biote Corp.

BTMDNASDAQ
Healthcare
Medical - Care Facilities
$2.06
$0.00(0.00%)
U.S. Market opens in 3h 24m

biote Corp. Fundamental Analysis

biote Corp. (BTMD) shows moderate financial fundamentals with a PE ratio of 2.30, profit margin of 14.72%, and ROE of -32.56%. The company generates $0.3B in annual revenue with moderate year-over-year growth of 6.38%.

Key Strengths

Cash Position42.23%
PEG Ratio-0.29

Areas of Concern

ROE-32.56%
We analyze BTMD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 26.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
26.2/100

We analyze BTMD's fundamental strength across five key dimensions:

Efficiency Score

Excellent

BTMD demonstrates superior asset utilization.

ROA > 10%
25.87%

Valuation Score

Excellent

BTMD trades at attractive valuation levels.

PE < 25
2.30
PEG Ratio < 2
-0.29

Growth Score

Moderate

BTMD shows steady but slowing expansion.

Revenue Growth > 5%
6.38%
EPS Growth > 10%
-29.15%

Financial Health Score

Excellent

BTMD maintains a strong and stable balance sheet.

Debt/Equity < 1
-1.46
Current Ratio > 1
1.01

Profitability Score

Weak

BTMD struggles to sustain strong margins.

ROE > 15%
-3255.73%
Net Margin ≥ 15%
14.72%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BTMD Expensive or Cheap?

P/E Ratio

BTMD trades at 2.30 times earnings. This suggests potential undervaluation.

2.30

PEG Ratio

When adjusting for growth, BTMD's PEG of -0.29 indicates potential undervaluation.

-0.29

Price to Book

The market values biote Corp. at -0.91 times its book value. This may indicate undervaluation.

-0.91

EV/EBITDA

Enterprise value stands at 0.49 times EBITDA. This is generally considered low.

0.49

How Well Does BTMD Make Money?

Net Profit Margin

For every $100 in sales, biote Corp. keeps $14.72 as profit after all expenses.

14.72%

Operating Margin

Core operations generate 16.09 in profit for every $100 in revenue, before interest and taxes.

16.09%

ROE

Management delivers $-32.56 in profit for every $100 of shareholder equity.

-32.56%

ROA

biote Corp. generates $25.87 in profit for every $100 in assets, demonstrating efficient asset deployment.

25.87%

Following the Money - Real Cash Generation

Operating Cash Flow

biote Corp. produces operating cash flow of $61.08M, showing steady but balanced cash generation.

$61.08M

Free Cash Flow

biote Corp. generates strong free cash flow of $53.12M, providing ample flexibility for dividends, buybacks, or growth.

$53.12M

FCF Per Share

Each share generates $1.11 in free cash annually.

$1.11

FCF Yield

BTMD converts 34.53% of its market value into free cash.

34.53%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

2.30

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.29

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.91

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.52

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.46

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.01

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.33

vs 25 benchmark

ROA

Return on assets percentage

0.26

vs 25 benchmark

ROCE

Return on capital employed

0.57

vs 25 benchmark

How BTMD Stacks Against Its Sector Peers

MetricBTMD ValueSector AveragePerformance
P/E Ratio2.3029.45 Better (Cheaper)
ROE-32.56%779.00% Weak
Net Margin14.72%-24936.00% (disorted) Strong
Debt/Equity-1.460.26 Strong (Low Leverage)
Current Ratio1.014.65 Neutral
ROA25.87%-19344.00% (disorted) Strong

BTMD outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews biote Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-60.37%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-96.72%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-60.56%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ